La vendita allo scoperto per Stereotaxis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Stereotaxis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Stereotaxis (AMEX:STXS) Azioni, Report sulle vendite allo scoperto

Stereotaxis

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Stereotaxis Inc

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Stereotaxis to report an earnings per share (EPS) of $-0.05.
Anticipation surrounds Stereotaxis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 11.67% increase in the share price the next day.
Here's a look at Stereotaxis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731081819_0.png" alt="eps graph" />
<h3>Tracking Stereotaxis's Stock Performance</h3>
Shares of Stereotaxis were trading at $1.84 as of November 07. Over the last 52-week period, shares are up 31.25%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STXS/earnings">To track all earnings releases for Stereotaxis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

STXS

Stereotaxis Earnings Preview

Health Care

General

Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. The company reported quarterly sales of $4.502 million which missed the analyst consensus estimate of $5.625 million by 19.96 percent. This is a 42.72 percent decrease over sales of $7.859 million the same period last year.

Earnings Misses

News

Stereotaxis Q2 2024 GAAP EPS $(0.07) Misses $(0.05) Estimate, Sales $4.502M Miss $5.625M Estimate

WIIM

Stereotaxis shares are trading higher after the company achieved CE Mark approval in Europe and submitted a 510(k) application to the FDA for its GenesisX Robotic System.

Stereotaxis Achieves CE Mark In Europe And Submits 510(k) To FDA For GenesisX Robotic System

AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>)&nbsp;came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this regenerative medicine company would post a loss of $0.10 per share when it actually produced a loss of $0.06, delivering a surprise of 40%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AxoGen, which belongs to the Zacks Medical - Instruments industry, posted revenues of $47.91 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 10.74%. This compares to year-ago revenues of $38.16 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
AxoGen shares have added about 16% since the beginning of the year versus the S&amp;P 500&#39;s gain of 9%.
<h2>What&#39;s Next for AxoGen?</h2>
While AxoGen has outperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AxoGen: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $46.27 million in revenues for the coming quarter and -$0.19 on $178.53 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Stereotaxis Inc. (AMEX:STXS), has yet to report results for the quarter ended June 2024. The results are expected to be released on August 12.
This company is expected to post quarterly loss of $0.04 per share in its upcoming report, which represents a year-over-year change of +42.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Stereotaxis Inc.&#39;s revenues are expected to be $5.7 million, down 27.5% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2318917/axogen-axgn-q2-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2318917">To read this article on Zacks.com click here.</a>

Biotech

Earnings Beats

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

AXGN

AxoGen Q2 Earnings and Revenues Beat Estimates

The Dow Jones index closed higher by around 0.5% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Stereotaxis</h3>
<ul>
<li>The Trade: Stereotaxis, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>) Director Paul J Isaac <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 7,000 shares</a> at an average price of $1.86. To acquire these shares, it cost around $13,017.</li>
<li>What's Happening: On May 13, Stereotaxis posted weaker-than-expected quarterly sales.</li>
<li>What Stereotaxis Does: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures.</li>
</ul>
<h3 class="wp-block-heading">Mobile Infrastructure</h3>
<ul>
<li>The Trade: Mobile Infrastructure Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#NYSE">BEEP</a>) Director Jeffrey Osher <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,983 shares at</a> at an average price of $3.30. To acquire these shares, it cost around $19,750.</li>
<li>What's Happening: On May 15, Mobile Infrastructure named Paul Gohr as new CFO.</li>
<li>What Mobile Infrastructure Does: Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39355507/jim-cramer-says-hes-going-to-have-to-wait-on-sofi-but-recommends-this-great-little-indus">Jim Cramer Says He&#8217;s &#8216;Going To Have To Wait&#8217; On SoFi, But Recommends This &#8216;Great Little Industrial Company&#8217;</a>
<h3 class="wp-block-heading">Hyliion Holdings</h3>
<ul>
<li>The Trade: Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) Chief Commercial Officer Govindaraj Ramasamy <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares</a> at an average price of $1.50. The insider spent around $15,000 to buy those shares. </li>
<li>What's Happening: On June 5, Hyliion announced commencement of manufacturing of additive parts for KARNO Generator at Austin Headquarters.</li>
<li>What Hyliion Holdings Does: Hyliion Holdings Corp is a provider of electrified solutions for the commercial vehicle industry as well as other industries.</li>
</ul>
<h3 class="wp-block-heading">FlexShopper</h3>
<ul>
<li>The Trade: FlexShopper, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) Director Howard Dvorkin <a href="https://www.benzinga.com/quote/FPAY/analyst-ratings">acquired a total of 12,845 shares</a> at an average price of $1.22. The insider spent around $15,621 to buy those shares.</li>
<li>What's Happening: On May 13, FlexShopper posted upbeat quarterly sales.</li>
<li>What FlexShopper Does: FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Long Ideas

Insider Trades

Pre-Market Outlook

Mobile Infrastructure Corporation Common Stock

BEEP

FPAY

HYLN

Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying

Stereotaxis Announces Penn Presbyterian Medical Center First Treats First Heart Rhythm Patients Using Genesis Robotic Magnetic Navigation System.

<a href="https://www.globenewswire.com/Tracker?data=v-8lZrL3Hbg-65FBgwZmSe4WzqRDScfhn5dMio0G2vQys3Nafm__mMXmrwMlbhudGeKCk_gacXahjI-zyZMg7g==">Stereotaxis</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. The recertification under MDR covers all Stereotaxis devices currently available in Europe.

Global

Stereotaxis Receives CE Mark Recertification Under EU's Medical Device Regulation Regulatory Framework

Stereotaxis Announces First Heart Rhythm Patients Treated With Robotic Ablation Procedures

<a href="https://www.globenewswire.com/Tracker?data=G0XsXOBib56JXFkySwt2mUU5_GpoSoP-lT9tomrgnGGR3V1q3BpbV3fedVYG9PehJDbIKw3c1CSnd5dQM8VJFg==">Stereotaxis</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to present at HRS Africa Summit 2024, scheduled to take place during Heart Rhythm Society Scientific Sessions this week in Boston, Massachusetts. &nbsp;
Stereotaxis will present an innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablation therapy in underserved regions of Africa. Africa is the second most populous and fastest growing continent, and yet has a nearly non-existent infrastructure of electrophysiology (EP) labs to provide cardiac ablation therapy. Cardiac ablation is a common minimally invasive procedure to treat arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Eighty percent of African countries do not have a single functional EP labi.

Stereotaxis Invited By Africa Heart Rhythm Association To Present its Robotic Solution To Expand High-Quality Therapy In Africa

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $6.880 million which missed the analyst consensus estimate of $7.000 million by 1.71 percent. This is a 5.07 percent increase over sales of $6.548 million the same period last year.

Stereotaxis Q1 2024 GAAP EPS $(0.06), Inline, Sales $6.880M Miss $7.000M Estimate

Stereotaxis Signs Definitive Agreement To Acquire Access Point Technologies

Lake Street analyst Frank Takkinen maintains Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) with a Buy and raises the price target from $3 to $4.

Price Target

Lake Street Maintains Buy on Stereotaxis, Raises Price Target to $4

Roth MKM analyst Jason Wittes reiterates Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) with a Buy and maintains $5 price target.

Reiteration

Roth MKM Reiterates Buy on Stereotaxis, Maintains $5 Price Target

Guidance

Stereotaxis Anticipates Double Digit Revenue Growth For Full Year 2024; Sees Q1 Revenue Of ~$7M (Est $6.70M)

<h3>Gainers</h3>
<ul>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 24.9% to $0.45 during Monday's after-market session. The company's market cap stands at $78.6 million. As per the news, the Q4 earnings report came out today. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock increased by 21.42% to $2.55. The company's market cap stands at $45.4 million. The company's, Q4 earnings came out today. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 20.48% to $0.17. The market value of their outstanding shares is at $8.7 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock rose 11.35% to $0.05. The company's market cap stands at $2.7 million. </li>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock increased by 11.12% to $4.89. The company's market cap stands at $55.5 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 6.15% to $1.38. The company's market cap stands at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares decreased by 15.0% to $0.85 during Monday's after-market session. The company's market cap stands at $46.3 million. As per the news, the Q4 earnings report came out today. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares decreased by 14.25% to $0.59. The market value of their outstanding shares is at $19.7 million. </li>
<li>Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares decreased by 9.13% to $28.3. The market value of their outstanding shares is at $1.8 billion. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 8.83% to $3.72. The company's market cap stands at $126.8 million. </li>
<li>Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) stock declined by 7.67% to $2.41. The market value of their outstanding shares is at $194.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) stock declined by 7.63% to $14.9. The market value of their outstanding shares is at $1.3 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

CARA

EKSO

JAGX

MBRX

OCEA

RBOT

SBFM

TARA

TLPH

TNDM

12 Health Care Stocks Moving In Monday's After-Market Session

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported its Q4 earnings results on Monday, March 4, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Stereotaxis missed estimated earnings by 0.0%, reporting an EPS of $-0.07 versus an estimate of $-0.07.
Revenue was down $2.74 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.01 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Stereotaxis's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.07</td>
<td>-0.07</td>
<td>-0.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.28M</td>
<td>6.68M</td>
<td>6.62M</td>
<td>8.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>7.80M</td>
<td>7.86M</td>
<td>6.55M</td>
<td>7.30M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Stereotaxis <a href="https://www.benzinga.com/quote/STXS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Stereotaxis Q4 Earnings

Stereotaxis Says Regulatory Submissions Were Made Recently In Both Europe And US For MAGiC Catheter

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.070) per share which met the analyst consensus estimate. The company reported quarterly sales of $4.565 million which missed the analyst consensus estimate of $7.700 million by 40.71 percent. This is a 37.47 percent decrease over sales of $7.301 million the same period last year.

Stereotaxis Q4 2023 GAAP EPS $(0.070), Inline, Sales $4.565M Miss $7.700M Estimate

Stereotaxis Q2 2024 Earnings Preview

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stereotaxis (STXS – Research Report), Neumora Therap...

Analysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Neumora Therapeutics, Inc. (NMRA)

Stereotaxis GAAP EPS of -$0.07 misses by $0.01, revenue of $4.5M misses by $1.13M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Stereotaxis (NYSEMKT:<a href="https://investorplace.com/stock-quotes/stxs-stock-quote/">STXS</a>) just reported results for the second quarter of 2024.<ul><li>Stereotaxis reported earnings per share of -7 cents. This was below the analyst estimate for EPS of -5 cents.</li><li>The company reported revenue of $4.50 million.</li><li>This was 19.89% worse than the analyst estimate for revenue of $5.62 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/stxs-stock-earnings-stereotaxis-for-q2-of-2024/">STXS Stock Earnings: Stereotaxis Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

STXS Stock Earnings: Stereotaxis Misses EPS, Misses Revenue for Q2 2024

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Stereotaxis (STXS – Research Report), with a price target of ...

Piper Sandler Sticks to Their Buy Rating for Stereotaxis (STXS)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stereotaxis (STXS – Research Report), Daré Bioscienc...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Lake Street analyst Frank Takkinen reiterated a Buy rating on Stereotaxis (STXS – Research Report) today and set a price target of $4.00. The compa...

Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

Stereotaxis (STXS) will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. ...

Stereotaxis' technology to be featured at SCRN Annual Meeting

CELC

DARE

ISRG

MCRPF

NMRA

RVMD

Press Releases

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

Management

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Stereotaxis Reports 2024 Second Quarter Financial Results

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

Stereotaxis to Present at Upcoming Investor Conferences

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024

University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

Alpha Tau Medical

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Stereotaxis

Vendite allo scoperto

Stereotaxis (AMEX:STXS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO